Susquehanna International Group
CLDI icon

Susquehanna International Group’s Calidi Biotherapeutics CLDI Stock Holding History

Susquehanna International Group’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-170
Closed -$18.5K – 12753
2025
Q1 		$18.5K Buy
170
+50
+42% +$9.12K ﹤0.01% 12128
2024
Q4 		$26.5K Sell
120
-3
-2% -$900 ﹤0.01% 11864
2024
Q3 		$26.8K Buy
+123
New +$34.2K ﹤0.01% 11560

Other funds holding CLDI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
CI
CPR Investments Rochester, Michigan $130M AUM 29.56% 1-Year Est. Return
RWI
Red Wave Investments Dillsburg, Pennsylvania $394M AUM 20.27% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group's CLDI Position: Q2 2025 in Review

Susquehanna International Group sold out of Calidi Biotherapeutics (CLDI) in Q2 2025, closing a stake of 170 shares — an estimated $18.5K sold.

Susquehanna International Group first reported a position in CLDI in Q3 2024 and held it in 3 quarters. The position peaked at $26.8K in Q3 2024. 34 funds tracked by Wall St. Rank hold CLDI as of Q2 2025.

  • Susquehanna International Group reported no remaining Calidi Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Susquehanna International Group sold 170 Calidi Biotherapeutics shares in Q2 2025, an estimated $18.5K.
  • Susquehanna International Group first reported a position in Calidi Biotherapeutics in Q3 2024 and held it in 3 quarters.
  • Susquehanna International Group's Calidi Biotherapeutics position peaked at $26.8K in Q3 2024.
  • 34 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2025.

Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.